Copper Peptides in Skincare: How to Read the Evidence

Copper peptides show up on serum and cream labels as "copper tripeptide-1," the ingredient-list name for GHK-Cu. This guide separates what has been tested in people from what rests on cell and animal work, and shows how to read a copper peptide claim on its own terms. It explains published research and product labels; it is not personal medical advice.

What GHK-Cu is

GHK is a small peptide made of three amino acids (glycine, histidine and lysine) that binds copper. It is found naturally in human plasma, saliva and urine, and reported levels fall with age ^{Source [1]}. Its copper complex is listed on cosmetic labels as copper tripeptide-1 ^{Source [2]}.

A label may also list palmitoyl tripeptide-1. That is a different ingredient: the same three-amino-acid chain with a fatty-acid tail attached, rather than a copper complex ^{Source [3]}. Evidence for one is not evidence for the other.

What has been tested in people

Most GHK-Cu research uses cell cultures and animals, where the peptide is linked to collagen production, wound repair and shifts in the activity of many genes ^{Source [4]}. Studies of topical products in people are few and small:

• After laser resurfacing. In a randomized study, patients used skin care with or without GHK-Cu after carbon dioxide laser treatment around the mouth; 13 completed it. Computer analysis and blinded evaluators found no difference between the groups in redness, wrinkles or overall skin quality, although patients in the GHK-Cu group rated their improvement higher on a questionnaire ^{Source [5]}.
• Eyebrow hair. A 2026 randomized, double-blind, split-face study in 18 healthy adults compared a 2% GHK-Cu serum on one eyebrow with a vehicle serum on the other for 12 weeks. The treated side showed higher hair counts and thicker hairs, and no serious side effects were reported ^{Source [6]}.
• Facial aging. The facial results most often repeated in marketing, from groups of 41 to 71 women over 12 weeks, are summarized in a 2015 review that cites conference proceedings, a university report and a book chapter for them, not full peer-reviewed trial reports. The review's authors list the research department of Skin Biology as their affiliation ^{Source [1]}.

A 2026 review that mapped the literature through August 2026 concluded that clinical evidence for GHK-Cu remains sparse, that older cosmetic reports are small or incompletely described, and that none of the human studies reported the chemical form of the test material in detail or how much intact complex reached the skin ^{Source [7]}. A 2025 review of topical GHK as an anti-wrinkle ingredient likewise found a "surprising absence of clinical studies" ^{Source [3]}.

A 2026 registry record for a topical GHK-Cu wound gel comes from a sponsor whose filings include records that describe themselves as fictional examples, so we do not count it as a trial ^{Source [8]}. A registered trial, when a real one appears, is a question being asked, not an answer.

Why lab and wound results do not transfer to a serum

Three gaps separate laboratory findings from a bottle on a shelf.

Skin is a barrier. Lab studies on donated human skin disagree depending on method. One found copper from the peptide passing through skin samples over 48 hours ^{Source [9]}. Another found almost no peptide or copper crossing intact skin over 9 hours, and far more after the skin was pretreated with microneedles ^{Source [10]}. Measuring copper alone also cannot show whether the intact peptide got through ^{Source [7]}.

Formulas differ. A study tests one formula, at one concentration, in one base. Another product that lists the same ingredient may contain a different amount in a different base, and the result does not automatically carry over.

Outcomes differ. Faster wound closure, more collagen in a cell dish and fewer visible lines are three different outcomes. Evidence for one is not evidence for the others.

Reading a copper peptide claim on a label

Four questions cover most claims:

1. Which ingredient? Look for copper tripeptide-1 in the full ingredient list, not just the word "peptides" on the front.
2. How much, and of what? US rules require ingredients to be listed from most to least, except that those at 1% or less may follow the rest in any order ^{Source [11]}. Labels do not have to state amounts ^{Source [12]}, and a percentage on the front may describe the pure peptide or a supplier's ingredient solution.
3. Which study, of which product? Check whether a cited result comes from people, animals or cells, and whether it tested this formula or only the ingredient.
4. Who ran it? In drug and device research, industry-sponsored studies more often report favorable efficacy results than studies with other funding ^{Source [13]}. A cosmetic maker's own data deserves the same question.

As an example, The Ordinary's Multi-Peptide + Copper Peptides 1% Serum lists copper tripeptide-1 fourth in its published ingredient list and carries "1%" in its name. Its US product page does not say what the 1% measures and does not cite a study of the formula ^{Source [14]}. Our documentation review of that serum goes through its label and policies criterion by criterion.

Regulatory status

In the United States, cosmetic products and ingredients other than color additives do not need FDA approval before they are sold, and companies are responsible for their safety ^{Source [15]}. Whether a product is regulated as a cosmetic or a drug depends on its intended use, judged from its claims and other evidence ^{Source [16]}. That status covers finished products applied to skin. It says nothing about copper peptide preparations meant for other routes, which have different evidence and rules; see GHK-Cu: why product form and route matter.

To see how we grade evidence, read our methodology and how to read a peptide study.